Celecoxib-induced gastrointestinal, liver and brain lesions in rats, counteraction by bpc 157 or l-arginine, aggravation by l-name
Given the history of optic neuritis, electric shock-like sensations, and paresthesia
"BPC 157 and the healing of muscle, tendon and ligament injuries." Curr Pharm Des
GHK-Cu longevity depends heavily on storage conditions, with room temperature exposure limited to 1-2 weeks for lyophilized material
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Starting at 250-300mcg regardless of body weight, then adjusting based on response, often works better than jumping to weight-based higher doses
